GVAX immunotherapy for prostate cancer fails in Phase III
This article was originally published in Scrip
Cell Genesys has terminated one of its two pivotal Phase III trials for GVAX immunotherapy for advanced prostate cancer, its lead developmental candidate, after the trial's independent data monitoring committee (IDMC) saw a higher number of deaths in the experimental arm compared with the control arm. Shares in the US biotech plunged by 72% on Nasdaq on August 27th.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.